New 2-year data show the long-term effects of bimekizumab on hidradenitis suppurativa, indicating its potential as a valuable ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology arsenal.

Despite the recent rise in herbal supplement use, research suggests certain supplements may pose risks for patients with ...

In this article, we explore the top 10 of the most powerful health benefits of turmeric, backed by scientific research.

New “slow flower” farms grow beautiful blooms—without health-harming chemicals used by overseas operations that dominate the ...

HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...